Opthea Highlights Sozinibercept Research at Innovate Retina
Opthea Limited (NASDAQ: OPT), a leading biopharmaceutical company, recently announced an exciting development in the treatment of wet age-related macular degeneration (wet AMD) as it prepares for a significant presentation at the Innovate Retina Meeting. Scheduled for October 17, this event will take place in a major city and will showcase Opthea's innovative approaches and clinical studies.
Focus on Unmet Medical Needs
During the meeting, Dr. David Boyer, a prominent figure in ophthalmology, will provide an insightful update on Opthea's wet AMD program. The presentation will delve into the pressing medical needs associated with wet AMD and discuss the promising results from the Phase 2b trial of sozinibercept. Additionally, the discussion will cover the upcoming Phase 3 trials that aim to demonstrate the effectiveness of combining sozinibercept with anti-VEGF-A monotherapy.
What to Expect at the Innovate Retina Meeting
Session Details
The presentation is part of Session 4, titled 'New Routes and New Molecules', and is set to occur at 5:27 PM CT. Dr. Boyer will share critical insights regarding the advancements made with OPT-302, also known as sozinibercept.
Innovative Technologies in Retina Care
Innovate Retina is a premier gathering that focuses on transformative innovations in medical and surgical retina care. Topics will include the latest advancements in managing age-related macular degeneration (AMD), diabetic retinopathy, and ocular imaging. Moreover, discussions will encompass gene therapy, ocular inflammation treatments, and cutting-edge surgical technologies.
About Opthea Limited
Opthea is on a mission to develop novel therapies that address significant unmet needs in the treatment of retinal diseases, notably wet AMD and diabetic macular edema (DME). Its lead therapy, sozinibercept, is currently under rigorous examination in pivotal Phase 3 clinical trials. These trials are designed to confirm the enhanced efficacy of the combination therapy over standard anti-VEGF-A treatments.
Future Prospects and Ongoing Commitments
As Opthea moves forward, the company is committed to improving treatment outcomes for patients suffering from retinal diseases. The integration of new therapeutic strategies and the continued evaluation of sozinibercept could potentially lead to remarkable improvements in patient care. The insights gained from the upcoming presentation will surely influence future explorations for solutions in retinal health.
Contact Information for Inquiries
If you wish to inquire further regarding this presentation or Opthea's research, you can reach:
Investor Inquiries:
PJ Kelleher
LifeSci Advisors, LLC
Email: pjkelleher@lifesciadvisors.com
Phone: 617-430-7579
Media Inquiries:
Silvana Guerci-Lena
NorthStream Global Partners
Email: silvana@nsgpllc.com
Frequently Asked Questions
What is sozinibercept?
Sozinibercept is a novel therapeutic candidate developed by Opthea aimed at treating retinal diseases such as wet AMD.
When is the Innovate Retina Meeting scheduled?
The Innovate Retina Meeting will take place on October 17.
Who will present at the meeting?
Dr. David Boyer will provide key insights into Opthea's research during the meeting.
What areas will the presentation cover?
The presentation will include updates on unmet medical needs in wet AMD and clinical trial results related to sozinibercept.
How can I learn more about Opthea?
You can visit Opthea's official website for more information about their ongoing research and products.
